The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: A pilot study

N. F. Kalkers, F. Barkhof, E. Bergers, R. van Schijndel, C. H. Polman

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Progressive axonal loss is the most likely pathologic correlate of irreversible neurologic impairment in primary progressive multiple sclerosis. In a run-in versus treatment trial, we show that the neuroprotective agent riluzole seems to reduce the rate of cervical cord atrophy and the development of hypointense T1 brain lesions on magnetic resonance imaging.
Original languageEnglish
Pages (from-to)532-533
JournalMultiple Sclerosis
Volume8
Issue number6
DOIs
Publication statusPublished - 2002

Cite this